Hansa Biopharma AB (publ) (HNSBF)
USD 2.83
(0.0%)
USD 2.83
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -785.66 Million SEK | -42.03% |
| 2022 | -554.25 Million SEK | -2.04% |
| 2021 | -538.83 Million SEK | -29.79% |
| 2020 | -414.75 Million SEK | -17.79% |
| 2019 | -351.66 Million SEK | -43.94% |
| 2018 | -245.47 Million SEK | -42.01% |
| 2017 | -172.22 Million SEK | -60.0% |
| 2016 | -107.6 Million SEK | -65.09% |
| 2015 | -65.21 Million SEK | -179.66% |
| 2014 | -24.47 Million SEK | -33.63% |
| 2013 | -17.44 Million SEK | -6.83% |
| 2012 | -16.26 Million SEK | 41.44% |
| 2011 | -24.28 Million SEK | -39.52% |
| 2010 | -19.99 Million SEK | -30.17% |
| 2009 | -15.35 Million SEK | 0.75% |
| 2008 | -15.47 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -154.15 Million SEK | 11.83% |
| 2024 Q3 | -116.92 Million SEK | 35.55% |
| 2024 Q2 | -181.41 Million SEK | -17.68% |
| 2023 Q3 | -202.15 Million SEK | 11.51% |
| 2023 Q4 | -112.33 Million SEK | 44.43% |
| 2023 FY | - SEK | -42.03% |
| 2023 Q1 | -182.34 Million SEK | -47.09% |
| 2023 Q2 | -228.45 Million SEK | -25.28% |
| 2022 FY | - SEK | -2.04% |
| 2022 Q2 | -167.83 Million SEK | -24.3% |
| 2022 Q3 | -139.49 Million SEK | 16.89% |
| 2022 Q4 | -123.96 Million SEK | 11.13% |
| 2022 Q1 | -135.02 Million SEK | 17.27% |
| 2021 FY | - SEK | -29.79% |
| 2021 Q4 | -163.21 Million SEK | -10.15% |
| 2021 Q3 | -148.17 Million SEK | -11.95% |
| 2021 Q2 | -132.35 Million SEK | -27.65% |
| 2021 Q1 | -103.68 Million SEK | 0.32% |
| 2020 Q1 | -91.35 Million SEK | 16.63% |
| 2020 FY | - SEK | -17.79% |
| 2020 Q3 | -123.44 Million SEK | -21.23% |
| 2020 Q2 | -101.82 Million SEK | -11.47% |
| 2020 Q4 | -104.01 Million SEK | 15.74% |
| 2019 Q4 | -109.57 Million SEK | -17.57% |
| 2019 FY | - SEK | -43.94% |
| 2019 Q1 | -72.68 Million SEK | 10.73% |
| 2019 Q2 | -83.68 Million SEK | -15.14% |
| 2019 Q3 | -93.19 Million SEK | -11.36% |
| 2018 Q3 | -60.5 Million SEK | -2.95% |
| 2018 Q1 | -46.62 Million SEK | 4.55% |
| 2018 Q2 | -58.76 Million SEK | -26.05% |
| 2018 FY | - SEK | -42.01% |
| 2018 Q4 | -81.41 Million SEK | -34.56% |
| 2017 Q3 | -37.43 Million SEK | 16.63% |
| 2017 Q4 | -48.84 Million SEK | -30.47% |
| 2017 FY | - SEK | -60.0% |
| 2017 Q1 | -44.82 Million SEK | -33.91% |
| 2017 Q2 | -44.9 Million SEK | -0.17% |
| 2016 Q2 | -30.67 Million SEK | -53.79% |
| 2016 Q4 | -33.47 Million SEK | -24.2% |
| 2016 FY | - SEK | -65.09% |
| 2016 Q3 | -26.95 Million SEK | 12.13% |
| 2016 Q1 | -19.94 Million SEK | -4.49% |
| 2015 FY | - SEK | -179.66% |
| 2015 Q4 | -19.08 Million SEK | -37.06% |
| 2015 Q3 | -13.92 Million SEK | 38.09% |
| 2015 Q2 | -22.49 Million SEK | -115.07% |
| 2015 Q1 | -10.46 Million SEK | 18.08% |
| 2014 Q2 | -4.83 Million SEK | 17.47% |
| 2014 Q4 | -12.76 Million SEK | -135.53% |
| 2014 Q1 | -5.85 Million SEK | -31.8% |
| 2014 FY | - SEK | -33.63% |
| 2014 Q3 | -5.42 Million SEK | -12.14% |
| 2013 FY | - SEK | -6.83% |
| 2013 Q2 | -4.29 Million SEK | 0.0% |
| 2013 Q3 | -4.44 Million SEK | -3.47% |
| 2013 Q4 | -4.44 Million SEK | 0.0% |
| 2012 FY | - SEK | 41.44% |
| 2011 FY | - SEK | -39.52% |
| 2010 FY | - SEK | -30.17% |
| 2009 FY | - SEK | 0.75% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -1006.015% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -13151.494% |
| SQZ Biotechnologies Company | -64.14 Million USD | -1124.909% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -4423.138% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 935.479% |
| Mesoblast Limited | -62.38 Million USD | -1159.292% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -51048.694% |
| Genus plc | 73.7 Million USD | 1166.037% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -11783.339% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -22050.252% |
| Marizyme, Inc. | -34.28 Million USD | -2191.818% |
| ContraFect Corporation | -64.99 Million USD | -1108.74% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -8856.555% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -17258.267% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -55946.834% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -29610.132% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -33709.374% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -151560.084% |
| Accustem Sciences Inc. | -3.74 Million USD | -20871.199% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -1529.106% |
| EV Biologics, Inc. | -1.26 Million USD | -61903.722% |
| Q BioMed Inc. | -617.62 Thousand USD | -127107.478% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 22095.213% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -124134.906% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -34291.455% |
| Biomind Labs Inc. | -1.03 Million USD | -75843.14% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 8054.531% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -10871.077% |
| Skye Bioscience, Inc. | -13.54 Million USD | -5699.344% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -52721.209% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -3142576.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -20126.681% |
| IMV Inc. | -35.52 Million USD | -2111.695% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -4850.737% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -31302.116% |
| GB Sciences, Inc. | -1.41 Million USD | -55233.284% |
| Alpha Cognition Inc. | -9.7 Million USD | -7995.006% |
| HST Global, Inc. | -5303.00 USD | -14815457.232% |
| CSL Limited | 4.78 Billion USD | 116.406% |
| Halberd Corporation | -74.27 Thousand USD | -1057626.948% |
| Enzolytics Inc. | -2.12 Million USD | -36924.423% |
| Resverlogix Corp. | -11.74 Million USD | -6591.1% |
| Affymax, Inc. | -14.29 Million USD | -5396.111% |
| SYBLEU INC | -141.57 Thousand USD | -554864.647% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -25550.176% |
| argenx SE | -216.02 Million USD | -263.697% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -1319.738% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 64657.847% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -52316.162% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 207485.89% |
| AVAX Technologies, Inc. | -6.11 Million USD | -12753.18% |
| Zenith Capital Corp. | -8.6 Million USD | -9029.317% |
| Genscript Biotech Corporation | -248.71 Million USD | -215.886% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -4509796.102% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -32014.512% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -446241.063% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -1882.168% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -27063.916% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -74989.361% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 11684647.888% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -44795.397% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -40800.854% |
| BioStem Technologies, Inc. | -7.55 Million USD | -10301.19% |
| ONE Bio Corp. | 13.61 Million USD | 5871.442% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -433760.333% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -38094.895% |
| Agentix Corp. | -1.37 Million USD | -57174.69% |
| LadRx Corporation | 412.28 Thousand USD | 190665.461% |
| Cell Source, Inc. | -4.27 Million USD | -18288.864% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -213849.91% |
| Regen BioPharma, Inc. | 1.46 Million USD | 53694.31% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -83753.977% |
| NovAccess Global Inc. | -1.03 Million USD | -75824.94% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 8973.805% |
| Itoco Inc. | -1.86 Million USD | -41936.977% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -206861.962% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -70300.448% |
| Kadimastem Ltd | -2.62 Million USD | -29837.307% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -328425.612% |
| CytoDyn Inc. | -18.02 Million USD | -4257.807% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -994052.779% |
| Mobile Lads Corp. | -2.24 Million USD | -34956.37% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -6424538.155% |
| Qrons Inc. | -40.08 Thousand USD | -1960103.089% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -161667.467% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 149060.911% |
| Rebus Holdings, Inc. | -951 Thousand USD | -82515.037% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -73879.435% |
| International Stem Cell Corporation | 202 Thousand USD | 389045.05% |
| Bioxytran, Inc. | -3.82 Million USD | -20466.46% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1492432.295% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -31812.701% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -2090.384% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -1745831.111% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -28594.996% |
| Neutra Corp. | -181.24 Thousand USD | -433379.727% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -3797.361% |
| PureTech Health plc | -11.62 Million USD | -6657.28% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -3797.628% |
| IXICO plc | -707 Thousand USD | -111027.157% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -10123.409% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -1525.096% |
| CSL Limited | 4.73 Billion USD | 116.6% |
| Cellectis S.A. | -92.63 Million USD | -748.125% |